SEC Form 4 · accession 0001209191-17-041666
REATA PHARMACEUTICALS INC · RETA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Novo Holdings A/S
10% Owner
Period of report
Jun 22, 2017
Accepted (ET)
Jun 23, 2017 · 4:34 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001358762
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CLASS B COMMON STOCKF1 | — | Jun 22, 2017 | S | 1,200,000 | D | — | — | CLASS A COMMON STOCK | 1,200,000 | 1,201,969 | D |
Explanation of responses
- F1Class B Common Stock has no expiration date and is convertible at the holder's election on a 1-for-1 basis for no additional consideration into the Issuer's Class A Common Stock, at any time. The shares of Class B Common Stock generally converts to shares of Class A Common Stock upon sale or transfer, subject to certain exceptions.
- F2Private sale of Class B Common Stock pursuant to a Purchase Agreement dated June 22, 2017.
Remarks
Novo Holdings A/S (formerly known as Novo A/S) is a Danish limited liability company. The board of directors of Novo Holdings A/S (the "Novo Board"), which is currently comprised of Sten Scheibye, Goran Ando, Jeppe Christiansen, Steen Riisgaard, Lars Rebien Sorensen and Per Wold-Olsen, has shared investment and voting control over the securities of the Issuer held by Novo Holdings A/S (the "Shares") and may exercise such control only with the support of a majority of the Novo Board. As such, no individual member of the Novo Board is deemed to hold any beneficial ownership or reportable pecuniary interest in the Shares.